Upstream Bio, Inc.
UPBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. At a $381.5M market cap, Upstream Bio, Inc. ranks as a small-cap company within healthcare. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Market Cap
$381.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.43
EPS (TTM)
$-2.90
EPS (Fwd)
$-2.89
ROE
-41.8%
ROA
-27.8%
Cash
$294.6M
Total Debt
$1.1M
Free CF
-$90.3M
52W Change
-34.6%
Annual Financials
Cash vs Debt
Upstream Bio, Inc. holds $294.6M in cash against $1.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$90.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -41.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.2M (2022) to $2.9M (2025), reflecting a 135% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing UPB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.